BCL2 and leukemia: Since the clinical derivative of ABT-737 (ABT-199, Venetoclax; Abbvie) has been recently approved for the treatment of relapsed/refractory CLL with 17p deletion [9, 10], it is tempting to speculate that pharmacological inhibition of FAO using etomoxir could further improve the efficacy of bcl-2 inhibition in leukemia patients.